Livongo recruits former 23andMe President Andy Page

Livongo's connected blood glucose meter sends glucose data to the cloud, and its digital diabetes management service provides patients with advice based on this data. (Livongo)

Former 23andMe President Andy Page will join Livongo Health, a digital health company focused on chronic disease, as its president and chief financial officer.

Page will lead financial and operational functions and strategic growth initiatives, Livongo said in a statement.

“With over 25 years of leadership experience, Andy has worked with some of the most innovative consumer-facing companies leveraging the power of technology. His experience scaling data science driven technology companies will be a valuable addition to an already exceptionally strong management team," Livongo CEO Glen Tullman said in a statement. "Andy's operational experience will also be helpful in managing our accelerating growth and balancing that with our expansion into new products and markets."


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Livongo’s blood glucose meter is the first with downloadable updates

Livongo’s diabetes management program is built around a blood glucose meter, a device that the majority of diabetics use to manage their disease, says Amar Kendale, the company’s senior vice president of product. The connected meter, which comes with unlimited blood glucose test strips, automatically uploads glucose readings to a cloud-based platform.

Patients may view their glucose data online or through a mobile app. The system provides advice based on glucose readings in real time and allows users to share their data with their physician’s office and/or loved ones. Patients also have access to diabetes coaches who are on hand 24 hours a day to answer questions. The company raised $52.5 million in series D funding in March.

In February, Livongo teamed up with Voluntis to offer the latter’s insulin dose recommendation device, Insulia, as part of its diabetes management program. Physicians base a treatment plan on the patient’s profile, insulin prescription and blood glucose targets. Through an app or web portal, Insulia then provides dose recommendations to patients based on this information and their blood glucose data.

Suggested Articles

The Rady Children’s Institute for Genomic Medicine tapped Deloitte to help develop a network of flying drones to deliver genetic testing specimens.

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart.